News & Events

Under the guidance of the Suzhou Municipal Health Commission, hosted by the Suzhou Medical Device Industry Association, and co-organized by the Suzhou Center for Disease Control and Prevention, the "First Suzhou In Vitro Diagnostics Industry Development Conference" will be grandly held on June 26, 2025, at the new address of the Suzhou Center for Disease Control and Prevention – Building D, Room 310 (Broadcast Hall), No. 16 Guangqian Road, Xiangcheng District, Suzhou.

With the theme "Upholding Integrity while Innovating · Intelligence Leading the Future", this conference will focus on core topics such as regulatory policies for in vitro diagnostic reagents and interpretations of healthcare insurance policies for IVD products. It aims to bring together professionals from all sectors of the in vitro diagnostics industry, fostering collaboration across academia, research, and clinical practice to accelerate technological innovation and clinical application expansion, thereby driving high-quality development in the industry.

Since its establishment, Suzhou GenDx Technology Co., Ltd. has been committed to globalizing its 10-minute ERA (Enzymatic Recombinase Amplification) rapid nucleic acid testing technology, with the mission to tackle challenges in infection diagnostics and safeguard public health through genetic technology.

The company possesses globally independent intellectual property rights for its Enzymatic Recombinase Amplification (ERA) technology. This innovative method simulates the natural amplification and replication process of genetic material in organisms by engineering and optimizing a multi-enzyme system (including recombinase, exonuclease, polymerase, etc.). Under constant temperature conditions, ERA technology can amplify trace amounts of DNA/RNA target sequences billions of times within just 10–15 minutes.

Leveraging this core technology, GenDx has developed a series of cutting-edge products and solutions. Its flagship products—the GD-220 Isothermal Nucleic Acid Amplification Analyzer and the Mycoplasma pneumoniae Nucleic Acid Detection Kit—have been listed in Jiangsu Province’s Key New Technologies and Products Catalog (2024) for prioritized promotion and application.

At the inaugural Suzhou In Vitro Diagnostics (IVD) Industry Development Conference, GenDx will showcase its cutting-edge technologies and products, engaging in in-depth discussions with industry experts, scholars, and corporate representatives. During the event, the company is expected to share its latest achievements in IVD innovation and explore ways to further advance the application of diagnostic technologies in clinical practice. This initiative aims to contribute to the growth of the IVD industry in Suzhou and across China.

The participation of GenDx will undoubtedly add fresh highlights and dynamism to this conference. We eagerly anticipate GenDx’s remarkable contributions at the event and hope this gathering will foster deeper collaboration and knowledge exchange within the industry, collectively propelling the IVD sector to new heights.

Let us all look forward to June 26th, as we witness GenDx’s shining moment at this premier industry summit!